Literature DB >> 35991480

Checkpoint inhibition in hepatocellular carcinoma: Outsmarting the Squid Game.

Natasha Chandok1, Sanjeev Sirpal2, Eric M Yoshida3.   

Abstract

Entities:  

Keywords:  carcinomas; checkpoint; hepatocellular; hepatocellular carcinoma; immune checkpoint inhibitors; immunotherapy

Year:  2022        PMID： 35991480      PMCID： PMC9236585          DOI： 10.3138/canlivj-2022-0012

Source DB:  PubMed          Journal:  Can Liver J        ISSN： 2561-4444


× No keyword cloud information.
  11 in total

1.  IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.

Authors:  Stephen P Hack; Jessica Spahn; Minshan Chen; Ann-Lii Cheng; Ahmed Kaseb; Masatoshi Kudo; Han Chu Lee; Adam Yopp; Pierce Chow; Shukui Qin
Journal:  Future Oncol       Date:  2020-04-30       Impact factor: 3.404

2.  AASLD guidelines for the treatment of hepatocellular carcinoma.

Authors:  Julie K Heimbach; Laura M Kulik; Richard S Finn; Claude B Sirlin; Michael M Abecassis; Lewis R Roberts; Andrew X Zhu; M Hassan Murad; Jorge A Marrero
Journal:  Hepatology       Date:  2018-01       Impact factor: 17.425

3.  Prospective validation of the Barcelona Clinic Liver Cancer staging system.

Authors:  Umberto Cillo; Alessandro Vitale; Francesco Grigoletto; Fabio Farinati; Alberto Brolese; Giacomo Zanus; Daniele Neri; Patrizia Boccagni; Nela Srsen; Francesco D'Amico; Francesco Antonio Ciarleglio; Alessio Bridda; Davide Francesco D'Amico
Journal:  J Hepatol       Date:  2006-01-24       Impact factor: 25.083

4.  The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients.

Authors:  Jing-Houng Wang; Chi-Sin Changchien; Tsung-Hui Hu; Chuan-Mo Lee; Kwong-Ming Kee; Chih-Yun Lin; Chao-Long Chen; Tai-Yi Chen; Yu-Jie Huang; Sheng-Nan Lu
Journal:  Eur J Cancer       Date:  2008-03-11       Impact factor: 9.162

5.  Nonsurgical management of advanced hepatocellular carcinoma: a clinical practice guideline.

Authors:  B M Meyers; J Knox; R Cosby; J R Beecroft; K K W Chan; N Coburn; J Feld; D Jonker; A Mahmud; J Ringash
Journal:  Curr Oncol       Date:  2020-05-01       Impact factor: 3.677

6.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

Review 7.  Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date.

Authors:  Nicola Personeni; Tiziana Pressiani; Lorenza Rimassa
Journal:  J Hepatocell Carcinoma       Date:  2019-01-31

Review 8.  Advances in immunotherapy for hepatocellular carcinoma.

Authors:  Bruno Sangro; Pablo Sarobe; Sandra Hervás-Stubbs; Ignacio Melero
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-04-13       Impact factor: 73.082

9.  Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.

Authors:  Thomas Yau; Yoon-Koo Kang; Tae-You Kim; Anthony B El-Khoueiry; Armando Santoro; Bruno Sangro; Ignacio Melero; Masatoshi Kudo; Ming-Mo Hou; Ana Matilla; Francesco Tovoli; Jennifer J Knox; Aiwu Ruth He; Bassel F El-Rayes; Mirelis Acosta-Rivera; Ho-Yeong Lim; Jaclyn Neely; Yun Shen; Tami Wisniewski; Jeffrey Anderson; Chiun Hsu
Journal:  JAMA Oncol       Date:  2020-11-12       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.